TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -9.86%8.39B | 26.69%18.12B | 57.37%9.3B | -24.92%14.3B | -27.46%5.91B | 28.68%19.05B | 22.45%8.15B | 3.39%14.81B | -4.06%6.66B | 27.20%14.32B |
Operating income | -9.86%8.39B | 26.69%18.12B | 57.37%9.3B | -24.92%14.3B | -27.46%5.91B | 28.68%19.05B | 22.45%8.15B | 3.39%14.81B | -4.06%6.66B | 27.20%14.32B |
Cost of sales | 4.86%-4.32B | -24.51%-8.85B | -53.56%-4.54B | 1.63%-7.11B | 5.94%-2.96B | -27.17%-7.22B | -19.26%-3.15B | 1.13%-5.68B | 4.05%-2.64B | -13.42%-5.75B |
Operating expenses | 4.86%-4.32B | -24.51%-8.85B | -53.56%-4.54B | 1.63%-7.11B | 5.94%-2.96B | -27.17%-7.22B | -19.26%-3.15B | 1.13%-5.68B | 4.05%-2.64B | -13.42%-5.75B |
Gross profit | -14.64%4.06B | 28.84%9.27B | 61.19%4.76B | -39.15%7.2B | -41.00%2.95B | 29.62%11.83B | 24.54%5B | 6.42%9.13B | -4.07%4.02B | 38.46%8.58B |
Selling expenses | 13.63%-2.75B | -39.08%-6.4B | -85.61%-3.19B | 39.28%-4.6B | 43.58%-1.72B | -35.71%-7.58B | -24.58%-3.04B | -9.35%-5.59B | 0.43%-2.44B | -49.51%-5.11B |
Administrative expenses | -10.20%-512.15M | -10.47%-1.04B | -15.72%-464.75M | 3.08%-944.4M | -5.77%-401.61M | -37.77%-974.45M | -13.79%-379.7M | -3.07%-707.28M | -10.10%-333.68M | -24.24%-686.19M |
Research and development expenses | 14.57%-267.93M | -12.06%-685.63M | 1.23%-313.61M | 11.90%-611.83M | -7.75%-317.53M | -26.15%-694.44M | -20.13%-294.7M | -18.64%-550.47M | -17.38%-245.32M | -33.89%-464M |
Impairment and provision | -232.37%-158.77M | 7.02%-9.37M | -29.33%-47.77M | 27.42%-10.07M | 20.19%-36.94M | 74.17%-13.88M | -39.65%-46.28M | -198.32%-53.73M | 36.19%-33.14M | -119.87%-18.01M |
-Other impairment is provision | -232.37%-158.77M | 7.02%-9.37M | -29.33%-47.77M | 27.42%-10.07M | 20.19%-36.94M | 74.17%-13.88M | -39.65%-46.28M | -198.32%-53.73M | 36.19%-33.14M | -119.87%-18.01M |
Special items of operating profit | -78.55%14.83M | 712.16%294.3M | -24.19%69.13M | -80.79%36.24M | 18.56%91.19M | -28.22%188.63M | -47.42%76.91M | 61.93%262.77M | 74.22%146.27M | -13.61%162.28M |
Operating profit | -52.76%384.58M | 34.11%1.43B | 42.82%814.05M | -61.34%1.06B | -56.68%569.97M | 10.54%2.75B | 18.73%1.32B | 1.22%2.49B | -11.61%1.11B | 14.13%2.46B |
Financing cost | 20.07%-84.27M | 9.81%-199.05M | -6.97%-105.44M | 0.60%-220.7M | 10.34%-98.57M | 9.25%-222.03M | 2.63%-109.93M | 18.73%-244.67M | -1.25%-112.89M | -2.99%-301.05M |
Share of profits of associates | 51.34%-874K | -6.32%-3.7M | -9.51%-1.8M | 67.63%-3.48M | 79.00%-1.64M | 32.29%-10.75M | -60.66%-7.81M | -214.27%-15.87M | -194.01%-4.86M | 28.13%-5.05M |
Earning before tax | -57.64%299.43M | 45.76%1.22B | 50.46%706.81M | -66.67%840.11M | -60.78%469.77M | 13.01%2.52B | 20.96%1.2B | 3.50%2.23B | -13.16%990.37M | 16.05%2.15B |
Tax | 5.08%-85.29M | 243.97%171.54M | -86.30%-89.85M | 69.98%-119.14M | 74.78%-48.23M | -7.42%-396.86M | -19.40%-191.24M | 3.11%-369.45M | 13.90%-160.17M | -31.64%-381.32M |
After-tax profit from continuing operations | -65.29%214.14M | 93.64%1.4B | 46.36%616.96M | -66.05%720.97M | -58.13%421.54M | 14.12%2.12B | 21.26%1.01B | 4.93%1.86B | -13.02%830.2M | 13.16%1.77B |
Earning after tax | -65.29%214.14M | 93.64%1.4B | 46.36%616.96M | -66.05%720.97M | -58.13%421.54M | 14.12%2.12B | 21.26%1.01B | 4.93%1.86B | -13.02%830.2M | 13.16%1.77B |
Minority profit | -91.72%3.16M | 354.75%110.87M | 380.91%38.22M | -122.84%-43.52M | -89.66%7.95M | -3.46%190.57M | -21.72%76.85M | 6.59%197.39M | 3.00%98.18M | 44.66%185.18M |
Profit attributable to shareholders | -63.55%210.98M | 68.11%1.29B | 39.93%578.74M | -60.45%764.49M | -55.52%413.59M | 16.21%1.93B | 27.02%929.83M | 4.73%1.66B | -14.79%732.02M | 10.36%1.59B |
Basic earnings per share | -63.53%0.0419 | 68.12%0.2552 | 39.95%0.1149 | -60.45%0.1518 | -55.53%0.0821 | 16.20%0.3838 | 26.96%0.1846 | 4.72%0.3303 | -14.77%0.1454 | 5.70%0.3154 |
Diluted earnings per share | -63.53%0.0419 | 68.12%0.2552 | 39.95%0.1149 | -60.45%0.1518 | -55.53%0.0821 | 16.20%0.3838 | 26.96%0.1846 | 0.3303 | 0.1454 | |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.